Article Sidebar

Download
View Article
Statistic
Read Counter : 21 Download : 16

Main Article Content

Abstract

The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, has had profound effects on global health and economics since its emergence in late 2019. Over 770 million confirmed cases of COVID-19 have been reported worldwide, with millions of deaths attributed to the virus.  Studies have shown that individuals with T2DM are at a higher risk of severe illness and mortality if they contract COVID-19. The presence of diabetes, especially when poorly controlled, can exacerbate the inflammatory response to the virus. Patients with T2DM often have comorbidities such as cardiovascular disease, hypertension, and obesity, which further increase the risk of severe COVID-19 complications

Keywords

SARS-CoV-2 type 2 diabetes mellitus (T2DM) cytokine storm cardiovascular complications glycemic control

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
D.K, N., D.A , U., N.G, S., & S.A, P. (2024). DIABETES MELLITUS AND COVID-19. CARDIOVASCULAR COMPLICATIONS AND COURSE OF TYPE 2 DIABETES MELLITUS AFTER CORONAVIRUS INFECTION. Journal of Medical Genetics and Clinical Biology, 1(9), 1–4. https://doi.org/10.61796/jmgcb.v1i9.906
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. . M. Sabirov, M. Bobokulov, K. Khaitov, and B. Munavvarov, “Kidney transplantation: Medical and social problems and clinical approaches,” Journal of Medicine and Innovations, vol. 3, pp. 111-120, 2022.
  2. . S. I. Zaripov, I. A. Turaev, and S. S. Rakhimov, “Quality of life in patients with chronic kidney disease receiving program hemodialysis and possible ways of its correction,” Uzbek Medical Journal, vol. 3, no. 5, 2022.
  3. . Z. S. Istamovich, A. K. Sadullayevich, and A. N. Mirza-Bakhtiyarkhanovna, “The significance of autoantibodies in the pathogenesis of systemic sclerosis (literature review),” Journal of Biomedicine and Practice, vol. 8, no. 2, 2023.
  4. . M. B. Rakhimova, K. S. Akhmedov, S. S. Rakhimov, and S. I. Zaripov, “Extraskeletal manifestations in patients with ankylosing spondylitis,” Journal of Coastal Life Medicine, vol. 11, pp. 1315-1321, 2023.
  5. . S. I. Zaripov and M. B. Raximova, “Quality of life in patients with terminal stage renal disease receiving programmed hemodialysis,” Innovation in the Modern Education System, vol. 3, no. 26, pp. 228-229, 2023.
  6. . Z. F. Umarova, S. B. Jumanazarov, S. I. Zaripov, and R. M. Khaydarov, “Quality of life in patients with chronic kidney disease in the V stage receiving program hemodialysis and possible ways of its correction,” Journal of Medicine and Innovations, 2024.
  7. . S. I. Zaripov and N. M. B. Abdurakhmanova, “The relationship between systemic sclerosis and anti-fibrillarin antibodies,” Journal of Modern Educational Achievements, vol. 6, no. 6, pp. 235-238, 2024.
  8. . S. I. Zaripov and N. M. Abdurakhmanova, “Quality of life of end-stage renal disease (ESRD) patients receiving hemodialysis: Influencing factors and approaches to correction,” Texas Journal of Multidisciplinary Studies, vol. 21, pp. 14-17, 2023.